AHA 2018 | Endocarditis Prophylaxis More Limited after AHA 2007 Guidelines

The incidence of infective endocarditis had decreased after AHA 2007 recommendations. At present, some patients are not receiving antibiotic prophylaxis as they should.

Disminuye la profilaxis de endocarditis luego de las guías del 2007After AHA restricted the use of antibiotic prophylaxis in 2007, high-risk patients undergoing dental procedures were prescribed less antibiotics. These patients had always been prescribed antibiotic prophylaxis, regardless they had less restrictive guidelines.  

 

At the same time, we observe a surprising trend towards lower incidence of infections endocarditis, which calls our attention. All these cases were presented at AHA annual meeting in 2018, and simultaneously published in JACC.


Read also: AHA 2018 | Freedom Long-Term Follow-up: Still in Favor of CABG.


In moderate risk patients, there was a more appropriate reduction of antibiotic prophylaxis after the new recommendations, with a more modest reduction in endocarditis rate for this group.

 

Even though this is an observational study, and we are no table to establish a cause-effect relationship between prescription frequency and endocarditis incidence, these finding support guideline recommendations.

 

However, we should not drop our guard: all high-risk patients undergoing dental procedures should receive antibiotic prophylaxis (not those at moderate risk).

 

Researchers estimate antibiotic prophylaxis has fallen across all groups since 2007 AHA recommendations. The drop has affected 52% of low or unknown risk patients, 64% of patients at moderate risk and 20% of high-risk patients.

 

Original title: Antibiotic prophylaxis and incidence of endocarditis before and after the 2007 AHA recommendations.

Reference: Thornhill et al. J Am Coll Cardiol. 2018;72:2543-2554.

 

profilaxis-antibiótica


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...